Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.84
ARIA's Cash to Debt is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ARIA: 0.84 )
ARIA' s 10-Year Cash to Debt Range
Min: 0.8   Max: 24.17
Current: 0.84

0.8
24.17
Equity to Asset 0.17
ARIA's Equity to Asset is ranked higher than
52% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARIA: 0.17 )
ARIA' s 10-Year Equity to Asset Range
Min: -2.2   Max: 0.89
Current: 0.17

-2.2
0.89
F-Score: 2
Z-Score: -2.43
M-Score: -3.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -483.41
ARIA's Operating margin (%) is ranked higher than
61% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. ARIA: -483.41 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -483.41

-526300
58.61
Net-margin (%) -492.24
ARIA's Net-margin (%) is ranked higher than
60% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. ARIA: -492.24 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -492.24

-493975
194.03
ROE (%) -146.51
ARIA's ROE (%) is ranked higher than
55% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. ARIA: -146.51 )
ARIA' s 10-Year ROE (%) Range
Min: -523.41   Max: 93.23
Current: -146.51

-523.41
93.23
ROA (%) -55.01
ARIA's ROA (%) is ranked higher than
62% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ARIA: -55.01 )
ARIA' s 10-Year ROA (%) Range
Min: -120.13   Max: 92.14
Current: -55.01

-120.13
92.14
ROC (Joel Greenblatt) (%) -175.74
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. ARIA: -175.74 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2869.58   Max: 1329.95
Current: -175.74

-2869.58
1329.95
Revenue Growth (%) -45.70
ARIA's Revenue Growth (%) is ranked higher than
60% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. ARIA: -45.70 )
ARIA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 214.8
Current: -45.7

0
214.8
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ARIA Guru Trades in Q4 2013

George Soros 1,950,000 sh (New)
Paul Tudor Jones 18,432 sh (New)
Chuck Royce 686,602 sh (New)
Steven Cohen 93,800 sh (+66.96%)
Manning & Napier Advisors, Inc Sold Out
Columbia Wanger Sold Out
Louis Moore Bacon Sold Out
» More
Q1 2014

ARIA Guru Trades in Q1 2014

Jim Simons 2,248,846 sh (New)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 516,602 sh (-24.76%)
George Soros 500,000 sh (-74.36%)
» More
Q2 2014

ARIA Guru Trades in Q2 2014

George Soros 1,000,000 sh (+100%)
Jim Simons 4,399,981 sh (+95.66%)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 480,602 sh (-6.97%)
» More
Q3 2014

ARIA Guru Trades in Q3 2014

Stanley Druckenmiller 1,645,000 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (-8.32%)
Jim Simons 1,252,681 sh (-71.53%)
George Soros 150,000 sh (-85%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Reduce -85%0.04%$5.01 - $6.5 $ 7.1122%150000
George Soros 2014-06-30 Add 100%0.02%$6.3 - $8.52 $ 7.113%1000000
George Soros 2014-03-31 Reduce -74.36%0.08%$6.46 - $8.99 $ 7.11-8%500000
George Soros 2013-12-31 New Buy0.11%$2.2 - $18.8 $ 7.1138%1950000
Daniel Loeb 2013-06-30 Sold Out 0.94%$16.32 - $19.77 $ 7.11-60%0
Daniel Loeb 2012-12-31 Add 85.19%0.4%$18.93 - $25.16 $ 7.11-68%2500000
Andreas Halvorsen 2012-12-31 Sold Out 0.33%$18.93 - $25.16 $ 7.11-68%0
Daniel Loeb 2012-09-30 Reduce -35.71%0.39%$17.11 - $24.21 $ 7.11-64%1350000
Andreas Halvorsen 2012-09-30 New Buy0.33%$17.11 - $24.21 $ 7.11-64%1934500
Daniel Loeb 2012-06-30 New Buy1.1%$14.6 - $17.82 $ 7.11-56%2100000
George Soros 2012-06-30 Sold Out 0.15%$14.6 - $17.82 $ 7.11-56%0
George Soros 2012-03-31 New Buy0.15%$12.73 - $16.32 $ 7.11-48%635000
George Soros 2011-12-31 Sold Out 0.07%$8.03 - $12.5 $ 7.11-35%0
George Soros 2011-09-30 New Buy0.07%$7.63 - $13.34 $ 7.11-32%496847
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 16.40
ARIA's P/B is ranked higher than
61% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. ARIA: 16.40 )
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 125.8
Current: 16.4

1.69
125.8
P/S 29.40
ARIA's P/S is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. ARIA: 29.40 )
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 705
Current: 29.4

1.71
705
EV-to-EBIT -6.06
ARIA's EV-to-EBIT is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARIA: -6.06 )
ARIA' s 10-Year EV-to-EBIT Range
Min: -52.4   Max: 13.4
Current: -6.06

-52.4
13.4
Current Ratio 3.97
ARIA's Current Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARIA: 3.97 )
ARIA' s 10-Year Current Ratio Range
Min: 0.62   Max: 15.1
Current: 3.97

0.62
15.1
Quick Ratio 3.96
ARIA's Quick Ratio is ranked higher than
70% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. ARIA: 3.96 )
ARIA' s 10-Year Quick Ratio Range
Min: 0.52   Max: 14.95
Current: 3.96

0.52
14.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.49
ARIA's Price/Tangible Book is ranked higher than
67% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. ARIA: 16.49 )
ARIA' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 1133
Current: 16.49

0.86
1133
Price/Median PS Value 0.45
ARIA's Price/Median PS Value is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ARIA: 0.45 )
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 11.33
Current: 0.45

0.02
11.33
Earnings Yield (Greenblatt) -16.60
ARIA's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. ARIA: -16.60 )
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.5   Max: 42.7
Current: -16.6

7.5
42.7
Forward Rate of Return (Yacktman) -7.22
ARIA's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. ARIA: -7.22 )
ARIA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -53.7   Max: -1.2
Current: -7.22

-53.7
-1.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
creiter note on ARIA Jan 03 2010 

More From Other Websites
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Nov 25 2014
ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today Nov 24 2014
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014
7:35 am Ariad Pharm announced the marketing approval of Iclusig (ponatinib) in Australia Nov 24 2014
ARIAD PHARMACEUTICALS INC Financials Nov 14 2014
Stalking an Entry Into Ariad Pharmaceutical Nov 12 2014
10-Q for ARIAD Pharmaceuticals, Inc. Nov 09 2014
ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting Nov 06 2014
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting Nov 06 2014
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress Nov 05 2014
ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today Nov 05 2014
Ariad tops 3Q profit forecasts Nov 05 2014
Ariad tops 3Q profit forecasts Nov 05 2014
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 05 2014
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress Nov 05 2014
Q3 2014 ARIAD Pharmaceuticals Inc Earnings Release - Before Market Open Nov 05 2014
Will ARIAD (ARIA) Miss This Earnings Season? Nov 04 2014
ARIAD to Present at the Stifel 2014 Healthcare Conference Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK